Literature DB >> 8697629

Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies.

N M Bhat1, M M Bieber, F K Stevenson, N N Teng.   

Abstract

We have previously described two human cold agglutinin MoAbs 216 and A6(H4C5), that are derived from the VH4-34 (VH4.21) gene that bind specifically to a cell surface ligand on human B lymphocytes. In this study, we report that binding of 216 and A6(H4C5) leads to rapid killing of target B cells. This complement-independent cytotoxicity was measured by three independent assays, cell viability dye uptake on FACS, 3H-thymidine uptake, and the 3(4,5)-dimethylthiazol-2,5-diphenyl tetrazolium bromide (MTT) assay. Cytotoxicity was specific for CD20+ mononuclear cells in human spleen and peripheral blood. The MoAbs were also cytotoxic to human B cell lines Nalm-6, OCI-LY8, Arent and SUP-B8, but not to T cell lines HuT 78 and PEER. As observed by scanning electron microscopy, membrane pores were formed within 15 min of exposure to the MoAbs. Cytotoxic activity was dependent on MoAb concentration and temperature of exposure. Killing with greater at 4 degrees C than 37 degrees C. Sodium azide and EDTA did not block the cytotoxic activity. No DNA fragmentation typical of apoptosis was observed. This rapid cytotoxic activity, independent of physiologic cellular process and independent of complement, suggests a novel mechanism of all death via membrane perturbations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697629      PMCID: PMC2200465          DOI: 10.1046/j.1365-2249.1996.d01-733.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  A comparison of the characteristics of circulating anti-myeloperoxidase autoantibodies in vasculitis with those in non-vasculitic conditions.

Authors:  I C Locke; B Leaker; G Cambridge
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

2.  A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties.

Authors:  Thomas Tiller; Ingrid Schuster; Dorothée Deppe; Katja Siegers; Ralf Strohner; Tanja Herrmann; Marion Berenguer; Dominique Poujol; Jennifer Stehle; Yvonne Stark; Martin Heßling; Daniela Daubert; Karin Felderer; Stefan Kaden; Johanna Kölln; Markus Enzelberger; Stefanie Urlinger
Journal:  MAbs       Date:  2013-04-09       Impact factor: 5.857

3.  In vivo tumouricidal effects of LAD-1 monoclonal antibody on murine RL-male-1 lymphoma mediated by enhanced phagocytosis.

Authors:  M Ito; S Omoto; Y Kato; T Hayashi; N Mori; Y R Fujii
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 4.  Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.

Authors:  Yuniel Fernández-Marrero; Alejandro López-Requena
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 5.  Human innate B cells: a link between host defense and autoimmunity?

Authors:  Eric C B Milner; Jennifer Anolik; Amedeo Cappione; Iñaki Sanz
Journal:  Springer Semin Immunopathol       Date:  2005-01-05

6.  Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Authors:  Michaela Liedtke; Clare J Twist; Bruno C Medeiros; Jason R Gotlib; Caroline Berube; Marcia M Bieber; Neelima M Bhat; Nelson N Teng; Steven E Coutre
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

7.  VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

Authors:  Evgeny Arons; Tara Suntum; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Blood       Date:  2009-09-10       Impact factor: 22.113

8.  9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles.

Authors:  Danielle C Alcéna; James J Kobie; Denise A Kaminski; Alexander F Rosenberg; Jonelle L Mattiacio; Matthew Brewer; Stephen Dewhurst; Carrie Dykes; Xia Jin; Michael C Keefer; Ignacio Sanz
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

9.  Enhanced anti-tumor effect of trastuzumab in combination with cisplatin.

Authors:  Ichiro Naruse; Hisao Fukumoto; Nagahiro Saijo; Kazuto Nishio
Journal:  Jpn J Cancer Res       Date:  2002-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.